

Your Vision, Our Future

Olympus Group Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2017

Hiroyuki Sasa President and Representative Director Olympus Corporation November 2, 2016

Highlights

First-Half Performance

 Sales and income down YOY primarily due to foreign exchange influences, but previously announced forecasts (in 1Q) achieved for operating income, ordinary income, and net income

Full-Year Performance Forecasts

- Forecasts for net sales, operating income and ordinary income revised to reflect rapid appreciation of yen versus British pound and Chinese renminbi as well as current operating environment, forecast for net income unchanged
- Local currency basis operating income forecast unrevised in mainstay Medical Business

Progress of Medium-Term Management Plan (16CSP)

 Measures progressing steadily in accordance with strategies and several noteworthy results have been achieved




2Q of Fiscal 2017 Consolidated Performance

- 1 YoY: Net sales relatively unchanged after adjustment for foreign exchange influences despite difficult operating environment
- **2** vs. forecasts: All income figures exceeded forecasts announced in 1Q

| (Billions of yen) | FY2016 | FY2017 (Forecasts announced in 1Q) | FY2017 | YoY Change | YoY | vs. forecasts | After foreign exchange adjustment (YOY) |
|----------------------------------|-----------------|--|----------------|-------------------|-----------------|---------------|---|
| Net Sales | 395.8 | 366.0 | 350.0 | -45.8 | -12% | -4% | -1% |
| Operating income (% of sales) | 50.1 (12.7%) | 29.0 (7.9%) | 2 | -15.7 (-2.9pt) | -31% | +18% | -3% |
| Ordinary income (% of sales) | 43.5 (11.0%) | 25.0 (6.8%) | 28.8 (8.2%) | -14.7 (-2.8pt) | -34% | +15% | |
| Net income* (% of sales) | 35.8 (9.0%) | 20.0 (5.5%) | 22.2 (6.3%) | -13.6 (-2.7t) | -38% | +11% | |
| ¥/US\$ | ¥122 | ¥107 | ¥105 | -¥17 (vo | n appreciation) | | |
| ¥/Euro | ¥135 | ¥119 | ¥118 | | n appreciation) | | |
| Impact on net sales | +155 | -¥38.0 billion | -¥43.5 billion | -+17 (ye | | | |
| Impact on operating income | - | -¥15.0 billion | -¥14.3 billion | | | | |

1H (Apr.-Sept.)



OLYMPUS

Operating Environment Conditions

- 1 No change to outlook for rising medical needs and other medium-to-long-term operating environment conditions
- **2** Persistently opaque global economic outlook

Outlook in 1Q

- Slowdowns in China and other emerging economies
- Further yen appreciation sparked by Brexit
- Persistently low resource prices
- Kumamoto earthquake

2 Current Outlook

- Slowdowns in China and other emerging economies
- Unstable foreign exchange rates
- Ongoing historic lows for resource prices

1 Operating Environment during 16CSP Period

- Declining birthrates and aging populations •
- Rising medical needs
- Growing pressure to limit medical costs
- Increase in case numbers and decrease in facility numbers
- Diversification of customer needs in Scientific Solutions Business
- Contraction of digital camera market

<u>Steady progress in implementation of strategies for</u> <u>accomplishing 16CSP targets</u>



Forecasts of Consolidated Financial Results for Fiscal 2017

1 Previously announced forecast for net income to be achieved despite unfavorable foreign exchange rates and difficult operating environment

| (Billions of yen) | FY2016 (Results) | FY2017 (Initial forecasts) | FY2017 (Newest forecasts) | Change | YoY (%) | After foreign exchange adjustment |
|----------------------------------|---------------------|-------------------------------|------------------------------|---|--|-----------------------------------|
| Net Sales | 804.6 | 775.0 | 743.0 | -32.0 | -8% | +3% |
| Operating income (% of sales) | 104.5 (13.0%) | 77.0 (9.9%) | 72.0 (9.7%) | -5.0 (-0.2pt) | -31% | -1% |
| Ordinary income (% of sales) | 90.9 (11.3%) | 67.0 (8.6%) | 60.0 (8.1%) | -7.0 (-0.5pt) | -34% | |
| Net income* (% of sales) | 62.6 (7.8%) | 57.0 (7.4%) | 57.0 (7.7%) | _ (+0.3pt) | -9% | |
| EPS (Yen) | ¥183 | ¥167 | ¥167 | _ | -9% | |
| ¥/US\$ | ¥120 | ¥106 | ¥105 | -¥1 | -¥15 | |
| ¥/Euro | ¥133 | ¥117 | ¥117 | (yen appreciation) -¥0 (yen appreciation) | (yen appreciation) -¥16 (yen appreciation) | |




* Net income attributable to owners of the parent

Progress of Medium-Term Management Plan (16CSP) (1)

Business Strategies: Grow Medical Business —Expansion of Operations in Endoscope Field and Emerging Countries

- Double-digit YoY sales growth in Asia and Oceania
- Establishment of training center in Thailand to accelerate growth in Southeast Asia (July)



Exterior and interior of Thai-Training and Education Center (T-TEC)





OLYMPUS

Progress of Medium-Term Management Plan (16CSP) (2)

Business Strategies: Grow Medical Business—Expand Single-Use Device Business

- Realize ongoing sales growth in single-use device business by leveraging strengthened sales force and expanded product lineup
- Surgical energy devices: Steady increase in sales of strategic product THUNDERBEAT
 - Double-digit YoY growth in North America in 2Q on local currency basis



THUNDERBEAT





Endotherapy Devices



Endotherapy devices:

Benefits of sales force strengthening appearing in North American market, world's largest market for these devices

- 15% YoY growth in North America in 2Q on local currency basis
- Double-digit growth realized for 10 consecutive quarters YoY

Priority Strategy: Concentrate Management Resources

- <u>Shift management resources to growth fields</u>
- Transfer of Nippon Outsourcing Corporation to The Longreach Group (October 31)
- Extraordinary income of approx. ¥3.8 billion to be recorded in 3Q

Priority Strategy: Strengthen Corporate Governance

- Explain measures for improving Board of Directors' effectiveness to stock market
- Disclosure of results of Board of Directors' evaluation (June 28, also done in FY2016)
- Corporate governance explanatory forum conducted by chairman of Board of Directors (an outside director and an independent director) (September 28)







Your Vision, Our Future

Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2016

Yasuo Takeuchi Director, Vice President and CFO Olympus Corporation November 2, 2016

Consolidated Financial Results and Business Overview for the 2Q of Fiscal 2017 (FY Ending March 31, 2017)



2Q of Fiscal 2017 (1) Consolidated Financial Results

First-half operating income higher than forecast announced in 1Q due to benefits of thorough cost management
Operating margin of approx. 10% secured despite unfavorable foreign exchange rates

| | | | <u> (/ (p p /</u> | | | | | |
|-------------------|-------------------|--|-------------------|------------------|--------------------|-------------|------------------------|---------------|
| (Billions of yen) | | | FY2017 | | vs. forecasts anno | unced in 1Q | | After foreign |
| | | FY2016 (Forecasts FY2017 announced in 1Q) | | Change | % | YoY (%) | exchange adjustment | |
| Net sales | | 395.8 | 366.0 | 350.0 | -16.0 | -4% | -12% | -1% |
| Gross profit | (% of sales) | 262.8 (66.4%) | 242.2 (66.2%) | 232.8 (66.5%) | -9.4 | -4% | -11% | +1% |
| SG&A expenses | (% of sales) | 212.7 (53.7%) | 213.2 (58.3%) | 198.4 (56.7%) | -14.8 | -7% | -7% | +2% |
| Operating incom | e (% of sales) | 50.1 (12.7%) | 29.0 (7.9%) | 34.4 (9.8%) | +5.4 | +18% | -31% | -3% |
| Ordinary income | (% of sales) | 43.5 (11.0%) | 25.0 (6.8%) | 28.8 (8.2%) | +3.8 | +15% | -34% | |
| Net income* | (% of sales) | 35.8 (9.0%) | 20.0 (5.5%) | 22.2 (6.3%) | +2.2 | +11% | -38% | |
| ¥/US\$ | | ¥122 | ¥107 | ¥105 | | | | |
| ¥/Euro | | ¥135 | ¥119 | ¥118 | | | | |
| Impact on net sa | ales | - | -¥38.0 billion | -¥43.5 billion | | | | |
| Impact on opera | ting income | - | -¥15.0 billion | -¥14.3 billion | | | | |

1H (Apr.-Sept.)

OLYMPUS

* Net income attributable to owners of the parent


2Q of Fiscal 2017 (3) Medical Business

| _ | Net sales perating incomeOperating margin | | | | Results | | | | | | | |
|-------------|---|---------------------------------|-----------------|---------------------------------|--------------------|----------------------------|--------------|---|------------------|------------------|--------------|---|
| | | , | 2. <u>9</u> . 1 | | | 4 | <u>2Q</u> | | | <u>1</u> H | <u>I</u> | |
| (Billions o | of yen) <u>297.9</u> | | | (Billions of yen) | JulSept. 2015 | JulSept. 2016 | Yen bases | After foreign exchange adjustment | AprSept. 2015 | AprSept. 2016 | Yen bases | After foreign exchange adjustment |
| 300.0 - | | <u>271.8</u> | | Net sales | 158.5 | 141.8 | -11% | +3% | 297.9 | 271.8 | -9% | +3% |
| 250.0 - | 23% | 7106 | 21% | Gastrointestin al Endoscopes | 89.7 | 80.4 | -10% | +3% | 167.1 | 152.5 | -9% | +3% |
| 250.0 | | | | Surgical Device | 50.5 | 44.6 | -12% | +3% | 95.2 | 85.3 | -10% | +2% |
| 200.0 - | Gastrointestinal Endoscopes 167.1 | Gastrointestinal Endoscopes | | Endotherapy Devices | 18.3 | 16.8 | -8% | +6% | 35.6 | 33.9 | -5% | +8% |
| | | 152.5 | - 15% | OP Income | 42.8 | 34.2 | -20% | +3% | 67.9 | 56.6 | -17% | +2% |
| 150.0 - | | | 1370 | OP margin | 27% | 24% | - | - | 23% | 21% | - | - |
| 100.0 - | Surgical Device 95.2 67.9 | Surgical Device 56.6 85.3 | | busines | ses aftei | r adjustr | nent fo | i basis, sal r foreign e (Local Cur | xchange | influences | | |
| 50.0 - | Endotherapy | | | Gastrointestinal Endoscopes | • Positiv | ve sales gro | wth in As | sia and Ocean | ia on back o | f ongoing str | ong perf | ormance |
| 0.0 - | Devices 35.6 | Endotherapy Devices 33.9 | 0% | Surgical Device | •Firm s devices | | instay sur | rgical endosco | pes, THUND | ERBEAT, and | l other ei | nergy |
| | AprSept. 2015 | AprSept. 2016 | | Endotherapy Devices | | y sales gro prces and e | | oan, Europe, a lineups | and United S | itates thanks | to stren | gthened |



2Q of Fiscal 2017 (4) Scientific Solutions Business

Net sales Operating income



| | | Results | | | | | | | | |
|-------------------|------------------|------------------|--------------|---|------------------|------------------|--------------|---|--|--|
| | | 2 | <u>2Q</u> | | <u>1H</u> | | | | | |
| (Billions of yen) | JulSept. 2015 | JulSept. 2016 | Yen bases | After foreign exchange adjustment | AprSept. 2015 | AprSept. 2016 | Yen bases | After foreign exchange adjustment | | |
| Net sales | 25.7 | 21.8 | -15% | -3% | 48.5 | 40.2 | -17% | -6% | | |
| OP income | 2.6 | 0.7 | -71% | -29% | 3.3 | -0.6 | - | -80% | | |
| OP margin | 10% | 3% | - | - | 7% | - | - | - | | |

1.1

- Sales and income down due to foreign exchange influences, difficult operating environment, and delays in delivering certain products and in launching new products
 - Limited research budget execution primarily in developed countries, sluggish resource-related investment due to low resource prices, and investment austerity in domestic manufacturing industry in view of yen appreciation

2Q of Fiscal 2017 (5) Imaging Business

Mirrorless

20.4

Others

2.8

(1.4)

Apr.-Sept. 2016

| Net sales | Operating icome (loss) | <u>Results</u> | | | | | | | | |
|----------------|------------------------|-------------------|------------------|---------------------|--------------|---|------------------|------------------|--------------|---|
| of Yen) | | | | <u>2Q</u> <u>1H</u> | | | | | | |
| 41.5 | | (Billions of yen) | JulSept. 2015 | JulSept. 2016 | Yen bases | After foreign exchange adjustment | AprSept. 2015 | AprSept. 2016 | Yen bases | After foreign exchange adjustment |
| Compact 9.6 | | Net sales | 20.0 | 13.8 | -31% | -22% | 41.5 | 29.8 | -28% | -20% |
| | 20.9 | Compact | 4.6 | 2.7 | -41% | -3% | 9.6 | 6.5 | -32% | -26% |
| | 29.8 Compact | Mirrorless | 12.8 | 9.6 | -25% | -15% | 26.8 | 20.4 | -24% | -14% |
| | 6.5 | Others | 2.6 | 1.4 | -46% | -40% | 5.1 | 2.8 | -44% | -39% |
| Mirrorless | | Operating loss | -1.1 | -1.2 | - | - | 0 | -1.4 | - | - |
| 26.8 | | | | | | | | | | |

- Sales down close to 30% YoY due to market contraction and impacts of Kumamoto earthquake
- Sales in line with forecasts announced in 1Q despite difficult operating environment thanks to strong sales of existing mainstay mirrorless camera models



(Billions of Yen)

Others

5.1

Apr.-Sept. 2015

0

45.0

40.0

35.0

30.0

25.0

20.0

15.0

10.0

5.0

0.0

-5.0

Consolidated Balance Sheet (End of September 2016)

- Net assets: ¥355.2 billion due to negative foreign exchange adjustments as result of yen appreciation
- Interest-bearing debt: Down ¥23.4 billion, to ¥297.7 billion
- Equity ratio: Despite reduction in net assets due to foreign exchange adjustments, 39.2% as result of lower interest-bearing debt


| (Billions of yen) | End Mar. 2016 | End Sept. 2016 | Change | | End Mar. 2016 | End Sept. 2016 | Change |
|---|------------------|-------------------|-----------------|---|------------------|-------------------|------------------|
| Current assets (Digital camera inventories) | 520.7 (14.4) | 464.6 (12.2) | -56.1 (-2.2) | Current liabilities | 266.6 | 250.8 | -15.8 |
| Property, plant and equipment | 166.1 | 160.7 | -5.3 | Non-current liabilities (Incl. bonds/long-term loans payable) | 349.7 (264.5) | 294.7 (222.2) | -55.0 (-42.3) |
| Intangible assets | 150.8 | 127.1 | -23.7 | Net assets | 384.3 | 355.2 | -29.1 |
| Investments and other assets | 163.1 | 148.4 | -14.7 | (Equity ratio) | (38.2%) | (39.2%) | (+1.0pt) |
| Total assets | 1,000.6 | 900.8 | -99.8 | Total liabilities and net assets | 1,000.6 | 900.8 | -99.8 |

Interest-bearing debt : ¥297.7 billion (-¥23.4 billion from March 31, 2016)



Consolidated Balance Sheet (End of September 2016)—Topics

- Improve ratings
 - Issuer rating from Rating and Investment Information, Inc., raised from BBB+ to A- (October 7)
 - Ongoing reduction of interest-bearing debt and improvement of equity capital earn praise for contributing to recent improvements in finances





Consolidated Cash Flows (April to September 2016)

■ Free cash flow of positive ¥8.7 billion secured while conducting steady investments for business growth

| (Billions of yen) | | FY2016 2Q | FY2017 2Q | Change |
|-------------------|--------------------------------|-----------|-----------|--------|
| Net sales | | 395.8 | 350.0 | -45.8 |
| Operating income | | 50.1 | 34.4 | -15.7 |
| | (%) | 12.7% | 9.8% | -2.9pt |
| CF from | m operating activities | 54.9 | 41.4 | -13.5 |
| CF from | m investing activities | -27.5 | -32.7 | -5.3 |
| CF from | m financing activities | -43.1 | -24.2 | +18.9 |
| Cash flow | | -15.7 | -15.6 | -0.1 |
| Free cash f | low | 27.4 | 8.7 | -18.7 |
| Cash and ca | ash equivalents at end of year | 194.9 | 138.7 | -56.2 |
| Depreciatio | on and amortization | 19.4 | 22.7 | +3.3 |
| | on of goodwill | 5.0 | 4.2 | -0.8 |
| Capital exp | 5 | | | |
| Capital exp | | 31.8 | 28.4 | -3.4 |



Forecast for Fiscal 2017



Forecasts of Consolidated Financial Results for Fiscal 2017

- Profitability to be maintained on full-year basis with operating margin of approx. 10% realized through exhaustive cost management
- 2 Net income forecast unchanged from previously announced forecast of ¥57.0 billion in consideration of extraordinary income from transference of subsidiary stocks and reduced tax expenses due to recording of deferred tax income

| (Billions of yen) | | FY2017 (Forecasts announced in 1Q) | FY2017 (Newest forecasts) | Change | vs. forecasts announced in 1Q | vs. forecasts announced in 1Q after foreign exchange adjustment |
|-------------------|-------------------|--|------------------------------|------------------------|----------------------------------|---|
| Net sales | | 775.0 | 743.0 | -32.0 | -4% | -3% |
| Gross profit | (% of sales) | 513.8 (66.3%) | 496.0 (66.8%) | -17.8 (+0.5pt) | -3% | -2% |
| Operating income | e (% of sales) | 77.0 (9.9%) | 72.0 (9.7%) | -5.0 (-0.2pt) | -6% | -1% |
| Ordinary income | (% of sales) | 67.0 (8.6%) | 60.0 (8.1%) | -7.0 (-0.5pt) | -10% | |
| Net income* | (% of sales) | 57.0 (7.4%) | 57.0 (7.7%) | _ (+0.3pt) | 0% | |
| EPS | | ¥167 | ¥167 | _ | | |
| ¥/US\$ | | ¥106 | ¥105 | -¥1 (yen appreciation) | 2017/3 (D | vividend Forecast) |
| ¥/Euro | | ¥117 | ¥117 | -¥0 (yen appreciation) | Annual divid | end of ¥28 per share |
| Impact on net sa | les | _ | -¥90 billion | | L | |
| Impact on operat | ing income | _ | -¥40 billion | | | |

OLYMPUS

* Net income attributable to owners of the parent

Segment Forecasts for Fiscal 2017



Medical: Operating income to be secured on local currency basis

Scientific Solutions: Net sales and operating income forecasts revised to reflect first-half performance and current operating environment

3 Imaging: Forecasts include earnings improvements as result of not changing prices of readily affordable mirrorless camera models

| | (Billions of yen) | 2017/3 (Forecasts announced in 1Q) | 2017/3 (Newest forecasts) | Change | vs. forecasts announced in 1Q | vs. forecasts announced in 1Q after foreign exchange adjustment |
|----------------------|-------------------|--|------------------------------|---------------|-------------------------------|---|
| Medical | Net sales | 598.0 | 576.0 | -22.0 | -4% | -2% |
| Medical | Operating income | 120.0 | 117.0 | -3.0 | -3% | 0% |
| Scientific Solutions | Net sales | 96.0 | 89.0 | -7.0 | -7% | -6% |
| | Operating income | 4.0 | 1.0 | -3.0 | -75% | -63% |
| . . | Net sales | 62.0 | 65.0 | +3.0 | +5% | +5% |
| Imaging | Operating income | -4.0 | -3.0 | 3 +1.0 | _ | _ |
| Othors | Net sales | 19.0 | 13.0 | -6.0 | -32% | -32% |
| Others | Operating income | -6.0 | -6.0 | _ | _ | _ |
| Elimination and | Net sales | _ | _ | - | _ | _ |
| corporate | Operating income | -37.0 | -37.0 | - | _ | _ |
| Concelidated total | Net sales | 775.0 | 743.0 | -32.0 | -4% | -3% |
| Consolidated total | Operating income | 77.0 | 72.0 | -5.0 | -6% | -1% |





- This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
- Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
- Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.